Last quarter (Q3 2025), Bolt Biotherapeutics's total revenue was $2.17M, a decrease of -91.00% from the same quarter last year. In Q3, Bolt Biotherapeutics's net income was $-7.14M. See Bolt Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	$ 7.69M	$ 7.88M	$ 5.73M	$ 1.26M	$ 231.00K
Gross Profit	$ 7.69M	$ -53.67M	$ -67.39M	$ -74.39M	$ -40.13M
Operating Expenses	$ 80.74M	$ 22.53M	$ 22.93M	$ 18.39M	$ 9.06M
Depreciation and Amortization	$ 1.78M	$ 1.85M	$ 1.67M	$ 1.19M	$ 611.00K
EBITDA	$ -66.45M	$ -74.34M	$ -88.66M	$ -91.59M	$ -48.57M
Operating Income	$ -73.05M	$ -76.20M	$ -90.32M	$ -92.79M	$ -49.18M
Other Income/Expenses	$ 9.93M	$ 7.00M	$ 2.22M	$ -5.80M	$ -11.55M
Pretax Income	$ -63.12M	$ -69.20M	$ -88.10M	$ -98.59M	$ -60.73M
Net Income	$ -63.12M	$ -69.20M	$ -88.10M	$ -98.59M	$ -60.73M
Per Share Metrics
Basic EPS	$ -1.65	$ -1.83	$ -2.30	$ -2.79	$ -1.99
Diluted EPS	$ -1.65	$ -1.83	$ -2.30	$ -2.79	$ -1.99
Weighted Average Shares Outstanding	38.18M	37.81M	37.36M	37.40M	36.25M
Weighted Average Shares Outstanding (Diluted)	38.18M	37.81M	37.36M	37.40M	36.25M

Currency in USD

Bolt Biotherapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing